Ownership and insider activity for Lipocine Inc. (LPCN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement.
Price
| Price | $2.16 |
| Market Cap | $18M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-03 | Grissinger Michael | A-Award | 2,000 | $4K |
| 2026-08-03 | Grissinger Michael | |||
| 2026-06-29 | Patel Mahesh V. | A-Award | 52,781 | $131K |
| 2026-06-03 | Higuchi John W. | A-Award | 1,764 | $4K |
| 2026-06-03 | Jene Jill M. | A-Award | 1,764 | $4K |
| 2026-06-03 | Ono Richard Dana | A-Award | 1,764 | $4K |
| 2026-04-07 | Higuchi John W. | P-Purchase | 40,000 | $81K |
| 2026-04-06 | Higuchi John W. | P-Purchase | 123,000 | $252K |
| 2026-04-06 | Patel Mahesh V. | P-Purchase | 25,000 | $51K |
| 2026-04-02 | Patel Mahesh V. | P-Purchase | 25,000 | $50K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.6M | $3.2M | $8.1M | $9.7M | $19.2M | $3.0M | $3.1M | $4.8M | $6.2M | $5.2M |
| Short-term Investments | $21.3M | $18.3M | $7.2M | $4.3M | $449992 | $41.7M | $29.4M | $17.3M | $15.4M | $9.7M |
| Receivables | $38943 | $3.3M | $38514 | $16522 | $391 | $247253 | $659855 | $52254 | $120447 | $14189 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $27.2M | $25.2M | $20.8M | $19.6M | $25.3M | $46.4M | $34.1M | $22.9M | $22.3M | $16.9M |
| Property, Plant & Equipment | $103440 | $75070 | $18997 | $3554 | 0 | $7211 | $131589 | $116095 | $165075 | $104293 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $27.3M | $25.3M | $20.9M | $19.7M | $25.4M | $52.5M | $37.5M | $23.0M | $22.5M | $17.0M |
| Accounts Payable | $245915 | $598070 | $671280 | $1.2M | $1.6M | $1.3M | $600388 | $1.4M | $271696 | $971822 |
| Short-term Debt | 0 | 0 | $3.3M | $3.3M | $3.3M | $2.3M | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.3M | $6.3M | $4.5M | $5.0M | $6.6M | $5.6M | $1.7M | $2.6M | $1.5M | $2.5M |
| Long-term Debt | 0 | 0 | $6.9M | $3.8M | $2.3M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.3M | $6.3M | $11.4M | $13.4M | $10.0M | $6.9M | $1.9M | $2.6M | $1.5M | $2.5M |
| Retained Earnings | -$105.4M | -$126.4M | -$138.1M | -$151.1M | -$172.0M | -$172.7M | -$183.4M | -$199.8M | -$199.8M | -$209.4M |
| Total Equity | $26.0M | $19.0M | $9.4M | $6.3M | $15.3M | $45.6M | $35.6M | $20.4M | $21.0M | $14.5M |
| Total Debt | 0 | 0 | $10.3M | $7.1M | $5.6M | $2.3M | 0 | 0 | 0 | $449591 |
| Net Debt | -$26.8M | -$21.5M | -$5.0M | -$6.9M | -$14.1M | -$42.3M | -$32.5M | -$22.0M | -$21.6M | -$14.5M |
| Working Capital | $25.9M | $18.9M | $16.3M | $14.7M | $18.7M | $40.8M | $32.5M | $20.2M | $20.8M | $14.3M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 11.48 |
Profitability
| Return on Equity | -64.75% |
| Return on Invested Capital | -57.74% |
| Return on Assets | -49.72% |
| Gross Margin | 98.10% |
| Operating Margin | -800.82% |
| Net Margin | -755.13% |
Related companies: ADAP · ANL · BLRX · EDSA · ERNA · GOVX · LNAI
Explore sector: Healthcare · Biotechnology
More sections of LPCN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks